Eric Sherman

Eric Sherman at Memorial Sloan Kettering Cancer Center specializes in the clinical management of advanced thyroid cancer, with expertise in cabozantinib and other multi-kinase inhibitors. He has participated in pivotal trials including EXAM which established cabozantinib for medullary thyroid cancer and studies exploring its role in differentiated disease. His clinical research focuses on sequencing and combining targeted agents for optimal patient outcomes. He has contributed to understanding resistance patterns following first-line TKI failure.